XSpray Pharma AB (STU:6XP) FCF Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is XSpray Pharma AB FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. XSpray Pharma AB's Free Cash Flow for the three months ended in Dec. 2024 was €-7.02 Mil. XSpray Pharma AB's Revenue for the three months ended in Dec. 2024 was €0.00 Mil. Therefore, XSpray Pharma AB's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, XSpray Pharma AB's current FCF Yield % is -21.68%.

The historical rank and industry rank for XSpray Pharma AB's FCF Margin % or its related term are showing as below:

During the past 10 years, the highest FCF Margin % of XSpray Pharma AB was -362.03%. The lowest was -23358.84%. And the median was -6720.70%.

STU:6XP's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -126.31
* Ranked among companies with meaningful FCF Margin % only.

XSpray Pharma AB FCF Margin % Historical Data

The historical data trend for XSpray Pharma AB's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XSpray Pharma AB FCF Margin % Chart

XSpray Pharma AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

XSpray Pharma AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of XSpray Pharma AB's FCF Margin %

For the Biotechnology subindustry, XSpray Pharma AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XSpray Pharma AB's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XSpray Pharma AB's FCF Margin % distribution charts can be found below:

* The bar in red indicates where XSpray Pharma AB's FCF Margin % falls into.

Save Embed

;

Save Embed

;

XSpray Pharma AB FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

XSpray Pharma AB's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-22.996	/	0
	=	%

XSpray Pharma AB's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-7.024	/	0
	=	%

XSpray Pharma AB FCF Margin % Related Terms

Thank you for viewing the detailed overview of XSpray Pharma AB's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

XSpray Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XSpray Pharma AB (STU:6XP) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

XSPRAY:Sweden 0GHZ:UK

Address

Scheeles vag 2, Solna, SWE, SE-171 65

Website

https://www.xspraypharma.com

XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and XS00Y.

XSpray Pharma AB Headlines

No Headlines